Sanwa Kagaku Kenkyusho
As of the edition of 20 October 2026, Sanwa Kagaku Kenkyusho runs 11 drugs, 9 of them marketed; it is on route A at 0 targets and on route B at 4 targets.
Sources: ClinicalTrials.gov, FDA Orange Book and Purple Book, other approval registers, company records.
Drugs by status
| Status | Count |
|---|---|
| Marketed | 9 |
| Went quiet | 2 |
| Total | 11 |
Marketed drugs and when their US protection ends
| Drug | US protection | Route B rows |
|---|---|---|
| Metformin | none listed | 4 |
| Acetaminophen | none listed | 17 |
| Darbepoetin alfa | Ended 2013 (computed from the first US licence) | 1 |
| Lactulose | none listed | 0 |
| Methacholine | none listed | 3 |
| Anagliptin | none listed | 1 |
| Miglitol | none listed | 5 |
| Upacicalcet | none listed | 1 |
| Topiroxostat | none listed | 0 |
A route B row is one company at one target.
Where it needs a new molecule
Route A at 0 targets, route B at 4 targets.
All 4 rows on route A or B
In the product4 company-target rows on route A or B; 1 is not shown here, and no score is.
See all 4 targets where Sanwa Kagaku Kenkyusho needs a new molecule, with the facts behind eachRequest access. Nothing is shown until you do.
Where its trials are
- Hormones: 9 trials led
- Nutrition and metabolism: 7 trials led
- Eye: 2 trials led